ArticleThe Prostate2025
Transcriptomic Signatures of Monocyte-Derived Macrophages Associate With Androgen Receptor Pathway Inhibitor Progression in Prostate Cancer.
Article in The Prostate, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- FOXA1 loss drives basal/squamous de-differentiation of prostate cancer and induces an immunosuppressive tumor microenvironment.Nature communications · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundAndrogen receptor pathway inhibitors (ARPIs) have significantly improved clinical outcomes for patients with metastatic prostate cancer (PC) but acquired ARPI resistance remains universal. Maximizing ARPI treatment duration is crucial to optimal clinical outcomes, but current clinical tools to detect acquired ARPI resistance, including serum Prostate Specific Antigen (PSA) and radiographic disease monitoring, are limited in both sensitivity and specificity. Since prostate cancer disease progression is associated with an increase in systemic inflammation, we hypothesized that circulating monocytes and monocyte-derived macrophages (MDMs) in patients with PC would express an increased pro-inflammatory phenotype in the context of disease progression.
methodsMonocytes and MDMs were isolated from peripheral blood samples from 16 patients with PC who were receiving ARPI therapies and performed transcriptomic and functional analysis both alone and in ex vivo coculture with prostate tumor cells utilizing a novel microscale coculture platform.
resultsWe identified a pro-inflammatory transcriptional signature in MDMs cultured with tumor cells that was associated with current, recent, and impending disease progression. Furthermore, we found that the pro-inflammatory phenotype of MDMs derived from patients with clinical progression was associated with paracrine anti-tumorigenic signaling that sensitized tumor cells to ARPI treatment in vitro. Finally, a transcriptional score generated from the MDM transcriptional signature of progressing patients could accurately identify current treatment response status as well as patients with recent/impending changes in response status.
conclusionsDisease progression in patients with prostate cancer receiving ARPI therapy is associated with a pro-inflammatory gene signature in peripheral monocyte-derived macrophages. We were able to develop a scoring signature based on this pro-inflammatory gene signature that has the potential to identify patients with recent and impending changes in disease response status that is not detectable using conventional disease assessment criteria. Further research will be needed to validate these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.